ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Axitinib

Also written as “AG-013736”, “axitinib” and “OTX-TKI”.

Its studies are mostly in Carcinoma, Renal Cell · Carcinoma, Non-Small-Cell Lung · Macular Degeneration · Neoplasms · Carcinoma, led by 6 companies.

Drug pageAxitinib: every studyMany companies study it; this page follows only the 45 they lead. All 139 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since May 7, 200745 company-led studies, 4 open or runningNext primary completion: Jan 8, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer360 open or runningphase 3since May 7, 2007Oct 9, 2003none ahead
Ocular Therapeutixits history only54 open or runningphase 3since Jan 12, 2024Jun 1, 2018Jan 8, 2027phase 3 · NCT06495918
Arog Pharmaceuticalsits history only10 open or runningphase 2since Oct 6, 2006Oct 6, 2006none ahead
Merckits history only10 open or runningphase 3since Jul 29, 2016Jul 29, 2016none ahead
SFJ Pharma Ltd. IIits history only10 open or runningphase 3since May 11, 2012May 11, 2012none ahead
Strata Oncologyits history only10 open or runningphase 2since Oct 1, 2021Oct 1, 2021none ahead

Also a collaborator on its studies: Fortrea, Gilead Sciences and SFJ Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 21 studies since Oct 9, 2003.

  1. Feb 2, 2009Phase 2 study in Carcinoma, Renal CellNCT00835978 · 213 enrolled · United States, Czechia, Germany and more
  2. Feb 11, 2009Phase 1 study in Stomach NeoplasmsNCT00842244 · 22 enrolled · Japan, Korea, Republic of
  3. May 20, 2009Phase 1 study in Healthy VolunteersNCT00905814 · 60 enrolled · Singapore
  4. Jun 8, 20092 phase 1 studies in Healthy VolunteersNCT00918632, NCT00919204
  5. Jun 11, 2009Phase 3 study in Kidney NeoplasmsNCT00920816 · 492 enrolled · United States, Bosnia and Herzegovina, Bulgaria and more
  6. Nov 23, 2009Phase 1 study in Healthy VolunteerNCT01020136 · 42 enrolled · Singapore
  7. Sep 22, 2010Phase 2 study in Carcinoma, HepatocellularNCT01210495 · 224 enrolled · United States, Belgium, China and more
  8. Sep 23, 2011Phase 1 study in Carcinoma, Renal CellNCT01441388
  9. Nov 2, 2011Phase 1 study in Advanced Solid TumorsNCT01469052 · 36 enrolled · United States
  10. Nov 26, 2013Phase 1 study in CarcinomaNCT01999972 · 50 enrolled · United States, United Kingdom
  11. May 6, 2014Phase 1 study in Carcinoma, Renal CellNCT02133742 · 52 enrolled · United States
  12. Jan 25, 2016Phase 3 study in Carcinoma, Renal CellNCT02684006 · 886 enrolled · United States, Australia, Austria and more
  13. Aug 28, 2017Phase 1 study in Carcinoma, HepatocellularNCT03289533 · 22 enrolled · Japan
  14. Feb 28, 2018Phase 2 study in Carcinoma, Non-Small-Cell LungNCT03472560 · 61 enrolled · United States, Hungary, Italy and more

TargetBeta

“Vascular endothelial growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
lenvatinibruleEisaiphase 481
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
chiauranibruleChipscreen Biosciencesphase 315

Studies

All 36 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03472560Carcinoma, Non-Small-Cell Lung · United States, Hungary, Italy and more2TerminatedFeb 9, 202361
NCT03289533Carcinoma, Hepatocellular · Japan1CompletedAug 27, 201922
NCT02684006Carcinoma, Renal Cell · United States, Australia, Austria and more3CompletedAug 31, 2023886
NCT02133742Carcinoma, Renal Cell · United States1CompletedMar 31, 201752
NCT01999972Carcinoma · United States, United Kingdom1CompletedFeb 22, 201750
NCT01469052Advanced Solid Tumors · United States1CompletedJul 200436
NCT01441388Carcinoma, Renal Cell1WithdrawnNov 20130
NCT01210495Carcinoma, Hepatocellular · United States, Belgium, China and more2CompletedMar 3, 2014224
NCT01020136Healthy Volunteer · Singapore1CompletedFeb 201042
NCT00920816Kidney Neoplasms · United States, Bosnia and Herzegovina, Bulgaria and more3CompletedJul 27, 2012492
NCT00919204Healthy Volunteers · China1CompletedAug 200914
NCT00918632Healthy Volunteers · Belgium1CompletedJul 200930
NCT00905814Healthy Volunteers · Singapore1CompletedSep 200960
NCT00842244Stomach Neoplasms · Japan, Korea, Republic of1CompletedDec 200922
NCT00835978Carcinoma, Renal Cell · United States, Czechia, Germany and more2CompletedOct 2012213
NCT00828919Solid Tumors · United States, Czechia, France and more–CompletedAug 14, 202352
NCT00768755Carcinoma, Non-Small-Cell Lung · United States, Italy, Japan and more2CompletedMar 2011180
NCT00735904Carcinoma · Poland, Romania, South Africa and more2CompletedNov 201138
NCT00726752Neoplasms · Japan1CompletedApr 20106
NCT00692341Hepatic Insufficiency · United States1CompletedOct 200824
NCT00678392Kidney Neoplasms · United States, Australia, Austria and more3CompletedAug 31, 2010723
NCT00615056Colorectal Neoplasms · United States, Canada, France and more2CompletedMar 2011171
NCT00600821Carcinoma, Non-Small-Cell Lung · United States, Czech Republic, France and more2CompletedApr 2011118
NCT00569946Carcinoma, Renal Cell · Japan2CompletedFeb 26, 201064
NCT00471146Carcinoma, Pancreatic Ductal · United States, Argentina, Australia and more3CompletedJan 2009630
NCT00460603Colorectal Neoplasms · United States2CompletedApr 2012187
NCT00454649Neoplasms · United States, Poland, Spain1CompletedAug 2009102
NCT00447005Carcinoma · Japan1CompletedAug 200912
NCT00389441Thyroid Neoplasms · United States, Canada, China and more2CompletedSep 201252
NCT00282048Kidney Neoplasms · United States2CompletedFeb 200962
NCT00219557Pancreatic Neoplasms · United States, Belgium, Canada and more2CompletedMar 14, 2008111
NCT00094107Melanoma · United States, France2CompletedApr 200832
NCT00094094Lung Neoplasms · United States, Germany2CompletedJul 200732
NCT00094055Thyroid Neoplasms · United States2CompletedJan 200960
NCT00076024Breast Neoplasms · United States, Canada, Czech Republic and more2CompletedJan 2007174
NCT00071006Leukemia, Myeloid, Acute · United States2CompletedJul 200412

How it is read

Names in the registry

  • “AG-013736”, 23 entries
  • “axitinib”, 13 entries
  • “OTX-TKI”, 8 entries
  • “Axitinib (AG-013736)”, 8 entries
  • “AG-013736 (axitinib)”, 7 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.